COR2ED

Second-line treatment for advanced #HCC Prof. Dr. Arndt Vogel Rahul Gosain, MD, MBA Rohit Gosain, MD #OncologyBrothers #CORE2ED Humanitas University Humanitas Research Hospital

New from #SABCS2024: PYNNACLE trial update Did you know that TP53 mutations, long linked to cancer growth, were once deemed "undruggable"? New research is showing that targeting these mutations could become a reality. Prof. frederique penault-llorca and Dr. Ecaterina Dumbrava share expert insights into the PYNNACLE phase 1/2 study, presented at SABCS 2024. The study investigates rezatapopt as a monotherapy for patients with locally advanced or metastatic solid tumours harbouring a TP53 Y220C mutation, including those with metastatic breast cancer. In this video, the experts discuss: 1. The role of TP53 mutations and the significance of TP53 Y220C variant. 2. Efficacy and safety results of rezatapopt in patients with mBC harbouring the TP53 Y220C mutation. 3. The importance of genomic testing for identifying the TP53 Y220C mutation. 4. Potential implications for clinical practice and future perspectives. 📺 Watch the video update to learn more *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme is sponsored by PMV Pharma

Thank you for sharing Digestive Cancers Europe!

#GISeries: #Hepatocellular Ca 2/4: 2L Rx and when to switch with Lorenza Rimassa and Prof. Dr. Arndt Vogel 🌟IO, TKIs, #supponc in 2L 🌟AEs/Management Full 🗣️ - https://lnkd.in/e9btx99t - https://lnkd.in/etvwh4g4 - Also on the “Oncology Brothers” podcast #Oncology #Cancer #LiverCancer COR2ED #CME

New Podcast! Join Dr Andrew Dauber & Dr Marta Ramón Krauel as they explore short-stature conditions, including SPIGFD, with patient cases & practical insights.

📢 New insights in breast cancer (BC) from the EMERALD Trial subgroup analysis: ESR1 mutations and beyond!   Is elacestrant a game-changer for patients with ER+ metastatic BC who retain endocrine sensitivity despite acquired resistance? How can the findings from the latest subgroup analysis guide real-world clinical decisions in the second-line, post-ET+CDK4/6i?   📺 Join Dr Virginia Kaklamani as she reviews the latest subgroup analyses from the EMERALD trial, offering insights on:   ·      ER-driven progression post-ET+CDK4/6i ·      The impact of metastasis site, co-mutations (PIK3CA, TP53), HER2-low expression, and ESR1 variants (D538G, Y537S/N) on elacestrant’s efficacy and safety ·      The relevance of routine testing for ESR1 mutations via ctDNA at each disease progression This hypothesis-generating analysis provides key insights into personalised treatment strategies and the role of elacestrant in clinically relevant patient populations.   🔎 Are you curious about elacestrant’s efficacy and safety in complex settings, such as ESR1 and PIK3CA coexisting mutations?   Explore the discussion now and stay ahead in the evolving ER+/HER2- mBC treatment landscape.   📖 Want more details? Follow this link to learn more: https://lnkd.in/eXCweWwJ This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only. #MedicalEducation

We’re at #SABCS2024! 🎗️ Excited to dive into practice-changing data and emerging developments in breast cancer. Will you be there? Let’s connect! 💡 Healthcare Professionals: Discover how our educational programmes can support your practice. 🤝 Medical Affairs Teams: Let’s collaborate on impactful medical education. 🌍 Medical Societies & Patient Advocacy Groups: Partner with us to create meaningful educational initiatives. Together, we can make a difference in the fight against breast cancer. Reach out—we’d love to hear from you!

📺 Catch the highlights from the new #HCC podcast with Dr Rachna Shroff and the Oncology Brothers, Drs Rohit & Rahul Gosain, as they discuss the use of #IO in unresectable HCC and explore the most recent clinical trial data. Full podcast is available at https://lnkd.in/enJvXkYA #MedEd Supported by an independent educational grant from AstraZeneca

We hit 3,000! 🎉 COR2ED has surpassed 3,000 YouTube subscribers globally. 📈 How did we achieve such an increase and at speed? Through a focus on high-quality medical education with relevant, bite-sized and engaging audio/video content. 👏 Join other HCPs and see how our programmes will support you in delivering the best possible care for your patients. 🤝 Visit us now on YouTube ➡️ https://ow.ly/uGfx50U9gos #MedicalEducation

📣 Immunotherapy for HCC: Video update from #ESMO24 📣 How will new data on immunotherapy (IO) and IO-based treatments for HCC impact clinical practice? Dr Richard Finn joined us at ESMO to share his thoughts on new data presented at the congress and reveal his key clinical takeaways that HCPs need to know. Watch his video update and download the slides 👇📺 https://lnkd.in/etX55wFr Dr Finn reviews data from the following studies: ➡️ Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Rimassa L, et al. (Abstract 947MO, ESMO2024) ➡️ Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW Decaens T, et al. (Abstract 965MO, ESMO 2024) ➡️ Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study. Llovet J, et al. (Abstract LBA3, ESMO 2024) ➡️ Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) (Abstract LBA39, ESMO 2024) Yopp A, et al. AstraZeneca has provided a sponsorship grant towards this Independent Programme #MedicalEducation #Oncology